Genitourinary Cancer

A real-world survival analysis showed that patients with metastatic RCC treated with axitinib plus pembrolizumab did not experience significantly improved survival outcomes compared with patients treated with ipilimumab plus nivolumab.

The Pfizer-BioNTech COVID-19 vaccine induces similar levels of COVID-19 antibodies in patients with solid cancer compared with people without cancer.

A recent study demonstrated that patients with prostate cancer on active surveillance reported reduced PSA levels after a 12-week HIIT regime.

Patients with prostate cancer fared better following treatment with magnetic resonance-guided focused ultrasound focal therapy than with radical prostatectomy or radiation therapy, shows study presented at 2021 AUA Annual Meeting.

Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.

Patients with advanced RCC who received prior VEGF-targeted therapy tend to have longer survival outcomes with cabozantinib than with axitinib.

Obese men are more likely to have improved overall survival following treatment for mCRPC than man who are overweight or normal weight, analysis finds.

A global study revealed that patients and caregivers alike reported insufficient knowledge surrounding renal cell carcinoma.

Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.

Patients with nonmetastatic castration-resistant prostate cancer often undergo prolonged treatment periods, making the safety profile of therapies like darolutamide an important factor in optimum treatment selection.

Yoga has a positive impact on the vagus nerve, which influences how people think, remember, and feel, and therefore can improve the mental well-being of patients with prostate cancer.

Researchers identified a slower rate of health-related quality of life deterioration, as well as an ability to postpone locally invasive procedures, in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

Pembrolizumab has been granted full approval as a first-line treatment for a select population of patients with bladder cancer.

The Food and Drug Administration approved adjuvant nivolumab to treat urothelial carcinoma in patients who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.

Belzutifan, a hypoxia-inducible factor inhibitor, has been approved for treatment of adults with cancers related to von Hippel-Lindau disease.

Recently approved combination therapies have contributed to significantly improved survival rates in renal cell carcinoma.

The combination of pembrolizumab and lenvatinib has been FDA approved as a frontline therapy for the treatment of adult patients with advanced renal cell carcinoma.

Germline variation may cause men of African descent to have a higher risk of prostate than men of European descent.

Patients with metastatic castrate-resistant prostate cancer and PTEN-loss tumors experienced improved radiographical progression-free survival with ipatasertib plus abiraterone.

Patients with favorable-risk prostate cancer tended to move away from active surveillance to initiating treatment after receiving their Oncotype DX Genomic Prostate Score.

A diagnosis of COVID-19 was associated with an increased risk of respiratory problems and mortality in patients with urological cancer undergoing elective procedures for their disease.

The efficacy and health-related quality of life benefits associated with the combination of lenvatinib and pembrolizumab make it a favorable treatment for advanced renal cell carcinoma, says an expert from Memorial Sloan Kettering Cancer Center.

Adjuvant radiation therapy treatment yielded strong results in reducing all-cause mortality in patients with high-risk prostate cancer.

A presentation from the 2021 ASCO Annual Meeting highlights the current limitations of Cabozantinib as a treatment for RCC.